Marketwire -- London, UK; Brentwood, TN, US; 24 September 2008 - Protherics PLC
("Protherics" or the "Company") the international biopharmaceutical
company focused on critical care and
cancer, today reports the findings of further analyses of data from its
placebo-controlled phase 2b Digibind® (GSK) Efficacy Evaluation in
Pre-eclampsia ("DEEP") study. These new analyses, together with results
from a mechanistic study, were presented in two oral presentations at
the 16th World Congress of The International Society for the Study of
Hypertension in Pregnancy (ISSHP) in Washington DC, US this week.
